An investigational antiviral medication called remdesivir received an emergency use authorization from the FDA earlier this month for potential use in Covid-19 treatment. This was granted after a clinical trial showed that remdesivir could shorten recovery time in some patients hospitalized with severe Covid-19 infections.
With this FDA authorization, remdesivir can be distributed in the U.S. and administered intravenously as treatment for severe cases, even though it is not yet officially approved for use. The medication’s manufacturer, Gilead Sciences, has stepped up by donating 940,000 doses to the federal government. This donation would treat up to 55,000 patients (with variation depending on the length of treatment needed). The federal government will ship the medication to state health departments which will then allocate them to medical centers.
Prior to remdesivir, physicians had been limited in treatment options for severe cases of Covid-19. This emergency use authorization was granted through the FDA’s new Coronavirus Treatment Acceleration Program which currently is reviewing 144 active trials of therapeutic agents, as well as another 457 developmental programs in the planning stages. As research continues at accelerated rates, each day we move closer to better treatments in the Covid-19 crisis.
Remember, you can count on BioPlus in these tough times, and in the better days ahead.
Related Posts
Pharmacists: A Key Player for Happier Patients
It’s never much fun to face a serious health condition, but having a pharmacist in direct...
Introducing New Prostate Cancer Treatment, Available from BioPlus
A new medication has joined the ranks of potential treatment for prostate cancer. The FDA recently...
Tick, Tock. Time Matters in Oncology Treatment Starts
The time it takes from a cancer diagnosis to first treatment can make all the difference in a...
Patients Now Have ‘Fast and Easy’ Access to More Generic Oncology Medications
BioPlus Specialty Pharmacy today announces the expansion of its ‘Hope Delivered in 24 Hours’...